Abstract / Summary
Belimumab is the first biologic approved for children aged over 5 years with systemic lupus erythematosus (SLE); however, evidence on its long-term efficacy and safety remains limited. This meta-analysis synthesized available data to provide quantitative evidence for clinical decision-making. PubMed, Embase, Cochrane Library and Wanfang databases were searched for studies reporting belimumab outcomes in pediatric SLE. Random-effects models were used for single-arm analyses, and risk ratios (RRs) and mean differences (MDs) were calculated for double-arm comparisons. Sixteen cohort studies and trials were included. Belimumab reduced the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score by 10.16 points at 6 months and 17.71 points at 12 months from baseline. LLDAS was achieved 42% at 6 months and 79% at 12 months. Mean glucocorticoid dose decreased by 19.88 mg/day at 6 months and 11.84 mg/day at 12 months. The 12-month flare rate was 7%, and adverse event (AE) rates were 12% and 46% at 6 and 12 months, respectively. In lupus nephritis (LN), complete remission occurred in 88% at 6 months and 94% at 12 months. Compared with standard immunotherapy, belimumab produced significant greater SLEDAI score reduction (MD, 2.86; P < 0.001), fewer AEs (RR, 0.37; P = 0.004) and higher LN remission rates (RR, 1.26; P = 0.03) at 6 months and lower flare risk at 12 months (RR, 0.44; P = 0.02). In pediatric SLE, add-on belimumab improves disease control and safety at 6 months and reduces flare risk at 12 months compared with standard immunotherapy. PROSPERO: https://www.crd.york.ac.uk/prospero, CRD420251142943.
Primary Source
Rheumatology (Oxford, England)
Ask Prognia AI
Have questions about this meta-analysis?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.